SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces the publication of a peer-reviewed article in Nature Scientific Reports that describes the mechanism of action of the Company's Selective Cytopheretic Device (SCD) in the immunomodulation of excessive inflammation. "Immunomodulatory effects of a cell progressing device to ameliorate dysregulated hyperinflammatory disease states," authored by Angela J. Westover, H. David Humes and Christopher J. Pino, (2024) 14:12747, investigated the SCD as an evolving approach to treating organ dysfunction arising from hyperinflammation and the cytokine storm by processing leukocytes in an extracorporeal circuit.
SeaStar Medical Announces The Publication Of A Peer-Reviewed Article In 'Nature Scientific Reports' Describes The Mechanism Of Action Of The Co's Selective Cytopheretic Device In The Immunomodulation Of Excessive Inflammation
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.